Clinical Trial

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

Recruiting
View on ClinicalTrials.gov →
Summary
This study will examine the impact of anti-programmed cell death 1 (PD1) therapy given in the approved adjuvant therapeutic regimens upon the morphologic, histopathologic, molecular and immunologic as well as genomic features of atypical/dysplastic nevi (A/DN) in patients with a prior documented melanoma of Stages IIB, IIC, IIIA, IIIB, or IIIC and concurrent presence of two or more atypical nevi.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-09-13; most recent amendment 2026-01-22.
Status change: Not Yet Recruiting → Recruiting 2024-11-04
Trial Details
NCT Number NCT06599619
Lead Sponsor John Kirkwood
Collaborators: Melanoma Research Foundation, VeyTel Inc.
Conditions Melanoma
Enrollment 30 participants
Start Date 2025-02-20
Primary Completion 2029-05 (estimated)
Study Completion 2029-05 (estimated)
Updated on ClinicalTrials.gov 2026-01-26